Technical Analysis for EBS - Emergent Biosolutions, Inc.

Grade Last Price % Change Price Change
grade D 62.06 -0.86% -0.54
EBS closed down 3.86 percent on Thursday, January 17, 2019, on 1.72 times normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Down
See historical EBS trend table...

Date Alert Name Type % Chg
Jan 17 Fell Below 50 DMA Bearish -0.86%
Jan 17 Overbought Stochastic Strength -0.86%
Jan 16 Crossed Above 50 DMA Bullish -4.68%
Jan 16 MACD Bullish Centerline Cross Bullish -4.68%
Jan 16 Doji - Bearish? Reversal -4.68%
Jan 16 Overbought Stochastic Strength -4.68%
Jan 16 Upper Bollinger Band Touch Strength -4.68%
Jan 15 Outside Day Range Expansion -4.14%
Jan 15 Overbought Stochastic Strength -4.14%
Jan 14 Overbought Stochastic Strength -1.37%

Older signals for EBS ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Emergent BioSolutions, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and commercialization of specialized products for use in defense and commercial markets in the United States and internationally. The company operates in two segments, Biodefense and Biosciences. It markets BioThrax, an FDA licensed vaccine for the prevention of anthrax disease; and RSDL (decontamination lotion) product for removal or neutralization of chemical warfare agents from the skin. The company's development pipeline includes Anthrivig (Human Anthrax Immunoglobulin), a polyclonal anthrax therapeutic candidate; PreviThrax, a recombinant anthrax vaccine candidate, NuThrax (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant); BioThrax with a novel adjuvant; and Thravixa (Fully Human Anthrax Monoclonal Antibody), a therapeutic being studied for use against symptomatic anthrax infection. In addition, it develops TRU-016, a humanized anti-CD37 therapeutic candidate, based on its ADAPTIR (Modular Protein Technology) platform that is in Phase I/II clinical trials to treat chronic lymphocytic leukemia. Further, the company develops preclinical product candidates targeted for solid tumors, inflammatory bowel disease, graft versus host disease, rheumatoid arthritis, and a human vaccine to protect against influenza caused by a range of circulating H5 influenza strains. Emergent BioSolutions, Inc. was founded in 1998 and is headquartered in Rockville, Maryland.
Is EBS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 73.89
52 Week Low 42.67
Average Volume 427,160
200-Day Moving Average 58.5765
50-Day Moving Average 64.938
20-Day Moving Average 60.498
10-Day Moving Average 63.064
Average True Range 2.684
ADX 20.92
+DI 23.9432
-DI 19.5792
Chandelier Exit (Long, 3 ATRs ) 58.728
Chandelier Exit (Short, 3 ATRs ) 62.052
Upper Bollinger Band 66.4496
Lower Bollinger Band 54.5464
Percent B (%b) 0.68
BandWidth 19.675361
MACD Line 0.1265
MACD Signal Line -0.5841
MACD Histogram 0.7106
Fundamentals Value
Market Cap 2.57 Billion
Num Shares 41.1 Million
EPS 1.57
Price-to-Earnings (P/E) Ratio 39.87
Price-to-Sales 3.22
Price-to-Book 2.65
PEG Ratio 1.56
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 68.41
Resistance 3 (R3) 68.95 67.56 67.44
Resistance 2 (R2) 67.56 66.08 67.29 67.11
Resistance 1 (R1) 65.08 65.17 64.39 64.54 66.79
Pivot Point 63.69 63.69 63.34 63.42 63.69
Support 1 (S1) 61.21 62.21 60.52 60.67 58.41
Support 2 (S2) 59.82 61.30 59.55 58.09
Support 3 (S3) 57.34 59.82 57.76
Support 4 (S4) 56.80